Analysis Published by PrecisionLife Reveals Potential to Systematically Reposition Hundreds of Patented Drugs into New Indications to Address Unmet Medical Needs
News
AMSBIO has expanded its range of top quality, high-performance assay kits, antibodies, enzymes, and substrates for cellular metabolism research.
The Enterprise Strategy from Anglia Innovation Partnership LLP will kickstart investment into new businesses at Norwich Research Park.
Anglia Innovation Partnership LLP, the organisation that manages Norwich Research Park, has launched its Enterprise Strategy to kickstart investment into new businesses at the Park.
Presenters will explain how long-term and whole-cell hepatocyte models can be used to improve in-vitro in-vivo correlation predictions and advance drug discovery and development research
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it will host a symposium entitled “Innovative Models for ADME-Tox Research” at Hotel Odelya in Basel, Switzerland on June 22.
Polyspecific antibodies for cancer research
AMSBIO announce a new range of high-quality bispecific antibodies (BsAbs) and trispecific antibodies (TsAbs) that can used to provide enhanced cancer therapeutic efficacy and/or safety compared to what can be achieved with conventional monospecific antibodies.
AMSBIO offer an extensive range of aptamers targeting many human proteins linked to cancer. Aptamers bind to target molecules with the same affinity and specificity as antibodies but offer significant advantages, in particular a lack of immunogenicity, which makes them an ideal tool for cancer diagnosis and therapy.
AMSBIO announce the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications.
AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation.
In March 2021, the European Patent Office (EPO) Guidelines for Examination were updated to include a section devoted to the examination of antibody-related patent applications (Guidelines G-II, 5.6). This new section provided a much anticipated outline of the EPO requirements for different approaches to defining antibodies in patent claims (Guidelines G-II, 5.6.1) and helpful guidance in relation to the inventive step of antibodies in Europe (Guidelines G-II, 5.6.2).
We have previously discussed the cell and gene therapy boom in the United Kingdom. The industry is thriving not only in the UK, but around the world, and here we take a quick look at some of the major successes and deals that have taken place in the last few months.
Gene therapy deals